Auron Therapeutics files Form D for $12 million debt offering
The Wellesley, Massachusetts biotechnology company reported $7,118,141 already sold toward the offering, with 14 investors participating as of the filing date.
Auron Therapeutics, Inc., a Delaware corporation based in Wellesley, Massachusetts, filed a Form D notice with the Securities and Exchange Commission dated August 13, 2026, disclosing an exempt securities offering. The filing lists a date of first sale of August 10, 2026, and is marked as a new notice rather than an amendment.1
The offering consists of debt securities.1 The total offering amount is listed at $12,000,000, with $7,118,141 already sold and $4,881,859 remaining to be sold.1
The company reported a total of 14 investors who have already invested in the offering.1 Auron claimed the Rule 506(b) exemption under Regulation D.1
The company indicated it does not intend the offering to last more than one year.1 The filing also states the offering is not being made in connection with a business combination transaction such as a merger or acquisition.1
The minimum investment accepted from any outside investor is listed as $0.1 The filing shows no sales compensation was paid to any broker or dealer, with none listed for either recipient or associated broker-dealer fields.1 Sales commissions and finders' fees were both reported at $0.1 The amount of proceeds used for payments to executive officers, directors, or promoters was also listed as $0.1
Auron identified its industry group as biotechnology within health care.1 The company selected "Decline to Disclose" for its revenue range and aggregate net asset value range.1
Related persons named in the filing include Katharine Yen as executive officer and director, along with directors Alexandra Cantley, Briggs Duncan Morrison, Anna French, Pini Orbach, Serge Messerlian, and Victoria Richon.1 Yen signed the filing as Chief Executive Officer on August 13, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.